Support and Resistance Basics
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top 10 Correlated ETFs
MLND
Top 10 Correlated Stocks
MLND
In the News
Tempest and Millendo Announce Stockholder Approval of Merger
Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”
MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therapeutics, Inc. (NasdaqGS: MLND) (“the Company”) with Tempest Therapeutics, Inc. pursuant to which Millendo shareholders are expected to only own approximately 18.5% of the combined company, subject to adjustments. KSF is seeking to determine whether the merger and the process that led to it are
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND
NEW YORK, April 2, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Millendo Therapeutics, Inc. ("MLND" or the "Company") ( MLND ) relating to its proposed merger with Tempest Therapeutics, Inc. Under the terms of the agreement, MLND shareholders are expected to own 18.5% of the combined company. The investigation focuses on whether Millendo Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MLND
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair to Millendo shareholders. Upon completion of the merger, Millendo shareholders are expected to own approximately 18.5% of the combined company while pre-merger Tempest stockholders will own approximately 81.5% of the combined company. Halper Sadeh encourages Millendo shareholders to click here to
MLND Stock Price Falls Over 10% Pre-Market: Why It Happened
The stock price of Millendo Therapeutics Inc (NASDAQ: MLND) fell by over 10% pre-market. This is why it happened.
Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger
Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics moniker under ticker 'TPST,' focusing on advancing Tempest's oncology pipeline of small molecule candidates.
Millendo Therapeutics (MLND) Investor Presentation - Slideshow
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.57 | 1.86 | 0 | 0 | 0 | |
| Net income per share | -575.72 | -321.49 | -263.65 | -48.77 | -28.95 | |
| Operating cash flow per share | -432.07 | -287.28 | -229.28 | -45.11 | -24.2 | |
| Free cash flow per share | -450.16 | -288.28 | -229.63 | -45.55 | -24.22 | |
| Cash per share | 800.58 | 423.84 | 753.09 | 68.37 | 30.36 | |
| Book value per share | 757.4 | 405.52 | 708.98 | 65.52 | 26.82 | |
| Tangible book value per share | 757.4 | 405.52 | 708.98 | 65.52 | 26.82 | |
| Share holders equity per share | 757.4 | 405.52 | 708.98 | 65.52 | 26.82 | |
| Interest debt per share | 0 | 0 | 6.85 | 3.81 | 2.12 | |
| Market cap | 48.87M | 38.89M | 15.86M | 115.96M | 37.16M | |
| Enterprise value | 4.94M | 23.18M | -56.86M | 58M | 1.66M | |
| P/E ratio | -0.59 | -0.76 | -0.58 | -2.6 | -1.02 | |
| Price to sales ratio | 74.83 | 131.82 | 0 | 0 | 0 | |
| POCF ratio | -0.79 | -0.85 | -0.67 | -2.81 | -1.22 | |
| PFCF ratio | -0.76 | -0.85 | -0.67 | -2.79 | -1.22 | |
| P/B Ratio | 0.45 | 0.6 | 0.22 | 1.94 | 1.1 | |
| PTB ratio | 0.45 | 0.6 | 0.22 | 1.94 | 1.1 | |
| EV to sales | 7.56 | 78.59 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -0.06 | -0.47 | 2.13 | -1.31 | -0.05 | |
| EV to operating cash flow | -0.08 | -0.51 | 2.4 | -1.41 | -0.05 | |
| EV to free cash flow | -0.08 | -0.51 | 2.4 | -1.39 | -0.05 | |
| Earnings yield | -1.68 | -1.31 | -1.71 | -0.38 | -0.98 | |
| Free cash flow yield | -1.32 | -1.18 | -1.49 | -0.36 | -0.82 | |
| Debt to equity | 0 | 0 | 0.01 | 0.04 | 0.05 | |
| Debt to assets | 0.12 | 0.12 | 0.13 | 0.2 | 0.22 | |
| Net debt to EBITDA | 0.55 | 0.32 | 2.73 | 1.31 | 1.02 | |
| Current ratio | 8.82 | 8.81 | 8.5 | 5.68 | 5.12 | |
| Interest coverage | 0 | 0 | -200.55 | 43.74 | 0 | |
| Income quality | 0.75 | 0.89 | 0.87 | 0.92 | 0.84 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 33.14 | 62.16 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.04 | 0 | 0 | 0.01 | 0 | |
| Capex to revenue | -3.96 | -0.54 | 0 | 0 | 0 | |
| Capex to depreciation | -1.16 | -0.1 | -1.13 | -0.38 | -0.02 | |
| Stock based compensation to revenue | 14.11 | 23.37 | 0 | 0 | 0 | |
| Graham number | 3.13K | 1.71K | 2.05K | 268.14 | 132.18 | |
| ROIC | -0.69 | -0.72 | -0.36 | -0.73 | -1.02 | |
| Return on tangible assets | -0.67 | -0.7 | -0.32 | -0.59 | -0.84 | |
| Graham Net | 700.32 | 369.89 | 663.86 | 52.9 | 22.84 | |
| Working capital | 103.24M | 60.98M | 73.61M | 58.61M | 32.91M | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | 102.12M | 60.23M | 72.47M | 56.03M | 31.22M | |
| Invested capital | 0 | 0 | 0.01 | 0.08 | 0.08 | |
| Average receivables | 0 | 0 | 1.8M | 1.28M | 795K | |
| Average payables | 1.84M | 1.87M | 1.75M | 1.5M | 1.49M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 147.53 | 1.04K | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.47 | 0.35 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.76 | -0.79 | -0.37 | -0.74 | -1.08 | |
| Capex per share | -18.1 | -1 | -0.35 | -0.43 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
| Metric | History | 2019-06-30 | 2020-03-31 | 2020-06-30 | 2021-03-31 | 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -11.07 | -9.76 | -8.43 | -6.61 | -5.57 | |
| Operating cash flow per share | -11.85 | -8.26 | -6.21 | -9.33 | 0 | |
| Free cash flow per share | -12.15 | -8.28 | -6.21 | -9.33 | -0.07 | |
| Cash per share | 61.97 | 47.16 | 39.72 | 21.48 | 53.94 | |
| Book value per share | 61.69 | 44.43 | 35.48 | 20.21 | 37.94 | |
| Tangible book value per share | 61.69 | 44.43 | 35.48 | 20.21 | 37.94 | |
| Share holders equity per share | 61.69 | 44.43 | 35.48 | 20.21 | 37.94 | |
| Interest debt per share | 3.95 | 3.03 | 2.75 | 1.94 | 3.73 | |
| Market cap | 168.19M | 97.41M | 33.44M | 22.83M | 14.18M | |
| Enterprise value | 116.75M | 43.29M | -13.39M | -1.51M | -49.78M | |
| P/E ratio | -4.26 | -2.03 | -0.78 | -0.68 | -0.5 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -15.91 | -9.59 | -4.25 | -1.93 | 0 | |
| PFCF ratio | -15.52 | -9.56 | -4.25 | -1.93 | -168.79 | |
| P/B Ratio | 3.06 | 1.78 | 0.74 | 0.89 | 0.29 | |
| PTB ratio | 3.06 | 1.78 | 0.74 | 0.89 | 0.29 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -11.49 | -3.65 | 1.3 | 0.18 | -7.16 | |
| EV to operating cash flow | -11.04 | -4.26 | 1.7 | 0.13 | 0 | |
| EV to free cash flow | -10.77 | -4.25 | 1.7 | 0.13 | 592.65 | |
| Earnings yield | -0.06 | -0.12 | -0.32 | -0.37 | -0.5 | |
| Free cash flow yield | -0.06 | -0.1 | -0.24 | -0.52 | -0.01 | |
| Debt to equity | 0.04 | 0.04 | 0.05 | 0.06 | 0.03 | |
| Debt to assets | 0.19 | 0.2 | 0.21 | 0.19 | 0.36 | |
| Net debt to EBITDA | 5.06 | 4.57 | 4.54 | 2.9 | -9.2 | |
| Current ratio | 5.9 | 5.76 | 5.36 | 6.39 | 7.2 | |
| Interest coverage | 32.46 | 74.91 | 0 | 0 | -24.58 | |
| Income quality | 1.07 | 0.85 | 0.74 | 1.41 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 2.1 | -0.09 | 0 | 0 | -0.51 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 123.93 | 98.75 | 82.02 | 54.84 | 68.92 | |
| ROIC | -0.18 | -0.21 | -0.23 | -0.32 | -0.1 | |
| Return on tangible assets | -0.14 | -0.18 | -0.19 | -0.26 | -0.09 | |
| Graham Net | 48.84 | 37.2 | 30.22 | 16.86 | 32.35 | |
| Working capital | 53.58M | 53.41M | 43.99M | 24.8M | 60.7M | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | 51.21M | 51.22M | 41.88M | 23.32M | 43.11M | |
| Invested capital | 0.07 | 0.07 | 0.08 | 0.1 | 0.09 | |
| Average receivables | 1.21M | 918K | 255K | 300K | 0 | |
| Average payables | 1.95M | 1.79M | 1.08M | 811K | 3.75M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.18 | -0.22 | -0.24 | -0.33 | -0.15 | |
| Capex per share | -0.3 | -0.02 | 0 | 0 | -0.07 |
Company Profile
- Volume Average 140.98K
- Market Capitalization 20.19M
- Employee 12
- CEO Dr. Julia Owens
- Headquarters Ann Arbor,MICHIGAN,US
- IPO Date 2012-10-04
-
Website
http://www.millendo.com 
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
